Cowen reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Wednesday morning, AnalystRatings.com reports.
KURA has been the topic of a number of other reports. Wedbush reissued a positive rating on shares of Kura Oncology in a research report on Wednesday, September 4th. HC Wainwright reissued a buy rating and set a $29.00 price target on shares of Kura Oncology in a research report on Friday, August 2nd. Deutsche Bank began coverage on shares of Kura Oncology in a research report on Thursday, July 18th. They set a buy rating and a $28.00 price target on the stock. Zacks Investment Research cut shares of Kura Oncology from a hold rating to a sell rating in a research report on Tuesday, November 5th. Finally, JMP Securities reissued a market outperform rating and set a $22.00 price target on shares of Kura Oncology in a research report on Thursday, September 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. Kura Oncology presently has an average rating of Buy and a consensus target price of $26.11.
Kura Oncology stock traded up $0.39 during mid-day trading on Wednesday, hitting $15.53. 128,700 shares of the company’s stock were exchanged, compared to its average volume of 264,753. The stock has a 50 day moving average of $14.92 and a two-hundred day moving average of $16.88. The company has a current ratio of 23.50, a quick ratio of 23.50 and a debt-to-equity ratio of 0.03. Kura Oncology has a 1-year low of $11.01 and a 1-year high of $21.42. The stock has a market cap of $672.35 million, a P/E ratio of -9.03 and a beta of 2.57.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Kura Oncology by 35.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,833 shares of the company’s stock valued at $58,000 after acquiring an additional 1,009 shares in the last quarter. Meeder Asset Management Inc. lifted its position in Kura Oncology by 55.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,007 shares of the company’s stock worth $46,000 after buying an additional 1,073 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in Kura Oncology during the 2nd quarter worth about $25,000. Wells Fargo & Company MN lifted its position in Kura Oncology by 3.3% during the 2nd quarter. Wells Fargo & Company MN now owns 42,448 shares of the company’s stock worth $835,000 after buying an additional 1,346 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in Kura Oncology by 82,066.7% during the 2nd quarter. Bank of Montreal Can now owns 2,465 shares of the company’s stock worth $49,000 after buying an additional 2,462 shares in the last quarter. 84.97% of the stock is currently owned by institutional investors and hedge funds.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: Green Investing
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.